SCHEMBL17986908

SCHEMBL17986908

CC(C)(C)[Si](C)(C)OCc1cccnc1C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
TSHR P16473 2/20 0.47
CASP3 P42574 1/20 0.47
RAB9A P51151 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 3/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
EGLN1 Q9GZT9 1/20 0.43
KCNA5 P22460 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
BACE1 P56817 1/20 0.41
MAPT P10636 3/20 0.39
PKM P14618 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29770723 1.00 L3MBTL1 (0.47) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL29770728 0.83 KDM4E (0.53) L3MBTL1TSHRPOLBTDP1KMT2A
SCHEMBL17986906 0.83 KDM4E (0.53) L3MBTL1TSHRPOLBTDP1KMT2A
SCHEMBL15065360 0.81 BACE1 (0.44) L3MBTL1TSHRCASP3SENP8SENP7
SCHEMBL3443405 0.81 BACE1 (0.42) L3MBTL1POLBKMT2ALMNAKCNA5
SCHEMBL23996876 0.79 POLB (0.56) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL19511284 0.78 ALDH1A1 (0.47) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL7499938 0.78 BACE1 (0.41) L3MBTL1TSHRPOLBTDP1LMNA
SCHEMBL9128644 0.75 LMNA (0.50) L3MBTL1RAB9ATDP1KMT2ALMNA
SCHEMBL20201222 0.75 POLB (0.57) L3MBTL1TSHRCASP3RAB9ASENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 WO disclosed
WO-2016119707-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LIMITED (CN) 2016-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 L3MBTL1 4124/4885TSHR 4327/4885CASP3 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.